Primary Prevention of Coronary Heart Disease. Aryan Mooss, M.D., F.A.C.C. Faculty Disclosure. Aryan Mooss, MD Dr. Mooss has listed an affiliation with: Grant/Research Support- Medtronic Speakers Bureau- Novartis however, no conflict of interest exists for this conference. Objectives.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Aryan Mooss, M.D., F.A.C.C.
Aryan Mooss, MD
Dr. Mooss has listed an affiliation with:
Grant/Research Support- Medtronic
Speakers Bureau- Novartis
however, no conflict of interest exists for this conference.
Braunwald, 7th edition page 1058
Cumulative incidence of CVD adjusted for the competing risk of death for men and women according to aggregate risk factor (RF) burden at 50 years of age
IDEAL RISK FACTOR PROFILE
Lloyd-Jones, D. M. et al. Circulation 2006;113:791-798
Change in age-adjusted mortality from coronary heart disease (CHD), stroke, and non-CVD in the United States, 1950 to 2002.
National Heart, Lung, and Blood Institute: Morbidity and Mortality: 2004 Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD, National Heart, Lung, and Blood Institute, 2004, p 23
The Practice of Coronary Disease Prevention, 1996, p. 3
871,517 (36% all deaths)
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
In a recent study of 784 siblings (age 30-59) of patients hospitalized with CAD <60 years age and followed for 10 years, the incidence of CAD events was 20% as opposed to the Framingham estimate of 12%
Vardya, et al, Amer J Card 2007
2 mutations of the gene coding for the serine protease PCSK9 results in 28% and 15% reduction in LDL levels and 50-88% reduction in coronary events